Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lifted its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 351.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 22,800 shares of the company’s stock after buying an additional 17,753 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Sana Biotechnology were worth $93,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in SANA. Point72 Middle East FZE bought a new position in Sana Biotechnology during the 4th quarter valued at $37,000. Royal Bank of Canada lifted its position in shares of Sana Biotechnology by 74.5% during the second quarter. Royal Bank of Canada now owns 9,737 shares of the company’s stock worth $58,000 after purchasing an additional 4,157 shares during the last quarter. XTX Topco Ltd acquired a new position in Sana Biotechnology in the first quarter worth about $86,000. Hsbc Holdings PLC acquired a new position in Sana Biotechnology in the first quarter worth about $90,000. Finally, Tower Research Capital LLC TRC increased its holdings in Sana Biotechnology by 150.1% in the second quarter. Tower Research Capital LLC TRC now owns 12,043 shares of the company’s stock valued at $72,000 after buying an additional 7,228 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

Analysts Set New Price Targets

SANA has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Sana Biotechnology in a report on Friday, March 1st. JMP Securities upped their price target on Sana Biotechnology from $8.00 to $15.00 and gave the company a “market outperform” rating in a research report on Friday, March 1st.

Sana Biotechnology Trading Up 5.9 %

SANA opened at $9.01 on Friday. The company’s 50-day moving average price is $8.44 and its 200 day moving average price is $5.62. Sana Biotechnology, Inc. has a fifty-two week low of $2.74 and a fifty-two week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Thursday, February 29th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.03. During the same period in the prior year, the business earned ($0.40) EPS. Equities analysts expect that Sana Biotechnology, Inc. will post -1.02 EPS for the current fiscal year.

Insider Activity at Sana Biotechnology

In related news, Director Robert Nelsen bought 1,818,181 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were purchased at an average cost of $5.50 per share, with a total value of $9,999,995.50. Following the completion of the transaction, the director now directly owns 12,446,022 shares of the company’s stock, valued at $68,453,121. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 34.90% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.